Gilead Sciences, Inc. GILD
Set alert
At close · Oct 30
After hours · Oct 30, 7:59 PM ET
- YTD
- +39.06%
- 1 year
- +44.11%
- Open
- 170.00
- Prev close
- 165.61
- Mkt cap
- 211.81B
- Vol
- 11.43M
- Avg vol
- 6.04M
- EPS
- -2.65
- P/E
- 0.00
- Div yield
- 1.98%
More statistics
- Low
- 169.00
- High
- 175.65
- Forward P/E
- 17.22
- Beta
- 0.33
- Short ratio
- 3.40
- Inst. own
- 91.98%
- Dividend
- 3.28
- Ex-div date
- Sep 14, 2026
- Earnings
- Feb 9, 2027
- 50-d avg
- 150.33
- 200-d avg
- 139.65
- 1y target
- 160.19
5D chart
Events in this range
- Oct 29, 2026Earnings: 2.55; estimate 2.19; surprise 16.44%
- Oct 30, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 30, 2026Rating: Truist Securities · Buy → Buy
- Oct 30, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 30, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
Signals (144)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:20 AM | 2 days ago |
| RSI: Overbought | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
-
1 day ago benzinga.com
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.
2 days ago businesswire.com
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare…
-
2 days ago benzinga.com
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175
TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $160 to $175.
-
2 days ago benzinga.com
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.
-
2 days ago benzinga.com
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190
Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $165 to $190.
-
2 days ago benzinga.com
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.
2 days ago seekingalpha.com
Gilead: Q3 Earnings Overview - It's Time To Consider Selling After Stellar Year
Gilead Sciences, Inc. delivered its strongest growth in a decade, with Q3 revenues up 16% ex-Veklury and robust HIV franchise performance. GILD's HIV division remains dominant, but Biktarvy faces…
-
2 days ago benzinga.com
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $126 to $131.
2 days ago zacks.com
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
2 days ago zacks.com
GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks
Gilead Sciences, Inc. GILD raised its 2026 sales outlook following strong third-quarter growth while providing new details on a significant Biktarvy pricing headwind expected in 2028.
2 days ago seekingalpha.com
Gilead: The Business Is Growing, But The Valuation No Longer Works
Gilead Sciences faces valuation headwinds despite strong Q3 results and successful HIV, Trodelvy, and Yeztugo growth. Medicare pricing will reduce Biktarvy revenue by $1.5 billion annually starting…
2 days ago benzinga.com
Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation
Gilead stock rose after Q3 earnings beat Wall Street estimates and strong HIV drug demand prompted an increased 2026 sales forecast.
2 days ago benzinga.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.
2 days ago seekingalpha.com
Gilead Sciences: Why I Remain Bullish After Q3
Gilead Sciences had a strong Q3. Sales of Trodelvy, a Trop-2-directed antibody-drug conjugate approved for the treatment of breast cancer, were $506 million, up 41.7% YoY and 10.7% QoQ. On October…
2 days ago benzinga.com
These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results
Gilead Sciences, Inc. (NASDAQ:GILD) reported better-than-expected earnings for the third quarter on Thursday.
-
2 days ago benzinga.com
These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results
Gilead beats Q3 estimates, raises 2026 sales guidance but cuts EPS outlook; shares rise 4.1% as analysts lift price targets.
-
2 days ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $175
Cantor Fitzgerald analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $155 to $175.
-
2 days ago benzinga.com
Needham Maintains Buy on Gilead Sciences, Raises Price Target to $200
Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.
2 days ago seekingalpha.com
Gilead Sciences, Inc. (GILD) Q3 2026 Earnings Call Transcript
Gilead Sciences, Inc. ( GILD ) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury & Investor Relations Daniel O'Day - Chairman &…
2 days ago zacks.com
Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
2 days ago marketbeat.com
What Gilead Sciences (GILD) Said on Its Q3 Earnings Call
Gilead Sciences NASDAQ: GILD reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi…
2 days ago zacks.com
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.47 per share a year ago.
2 days ago benzinga.com
Gilead Sciences Q3 2026 Earnings Call Transcript
Gilead Sciences (NASDAQ:GILD) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
2 days ago benzinga.com
Gilead Sciences Q3 2026 Earnings Call Transcript
Gilead Sciences (NASDAQ:GILD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
3 days ago wsj.com
Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
The biopharmaceutical company said it now expects full-year product sales of $31 billion to $31.3 billion, up from $30.1 billion to $30.4 billion.
-
3 days ago benzinga.com
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) Est
Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) analyst estimate..
-
3 days ago benzinga.com
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) Est; Raises FY2026 Sales Guidance from $30.100B-$30.400B to $31.000B-$31.300B vs $30.767B Est
Gilead Sciences (NASDAQ:GILD) lowers FY2026 Adj EPS guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) analyst estimate. Raises FY2026 sales outlook from $30.100 billion-$30.400 billion to…
-
3 days ago benzinga.com
Gilead Sciences Q3 Adj. EPS $2.55 Beats $2.19 Estimate, Sales $8.300B Beat $7.809B Estimate
Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.19 by 16.44 percent. This is a 3.24 percent increase over earnings of…
3 days ago barrons.com
Gilead's HIV Franchise Powers Earnings Beat. The Rest Is a Work in Progress.
Gilead Sciences posts higher-than-expected sales as blockbuster HIV drug Biktarvy continues to drive its top line.
3 days ago businesswire.com
Gilead Sciences Announces Third Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026. “Gilead delivered an exceptional third…
3 days ago benzinga.com
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
3 days ago fool.com
Breakfast News: Brace for an AI Optics Shake-up
Bloomberg says Marvell could buy Lumentum, Fortinet sinks over 25%, and more…
4 days ago benzinga.com
Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test
Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
4 days ago 247wallst.com
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast.
5 days ago zacks.com
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.
5 days ago zacks.com
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
6 days ago zacks.com
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the…
6 days ago defenseworld.net
Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake
Citizens Financial Group Inc. RI boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 52.4% in the undefined quarter, according to the company in its most recent 13F filing with the…
1 week ago fool.com
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
Amgen and Gilead pay forward dividend yields above 2%. Gilead has a lower dividend payout ratio, but Amgen is generating stronger sales growth.
1 week ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 week ago benzinga.com
Gilead Sciences Agrees To Acquire Oral IL-23R Inhibitor Program From PepStar Therapeutics Under $1.275B Deal
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar…
-
1 week ago benzinga.com
BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer
Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb ("BMS").ROSETTA…
1 week ago benzinga.com
Occidental Petroleum To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts cut targets for WING, ELAN, SBAC and RH; raised targets for TRV, OXY and GILD, with ELAN downgraded to Hold.
-
1 week ago benzinga.com
B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172
B of A Securities analyst Tim Anderson maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $168 to $172.
1 week ago benzinga.com
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success
Gilead Sciences announced positive Phase 2 SWIFT trial results for emvistegrast, an oral treatment for active ulcerative colitis.
2 weeks ago benzinga.com
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
-
2 weeks ago benzinga.com
Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid…
-
2 weeks ago benzinga.com
Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and…
2 weeks ago benzinga.com
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.27% on an annualized basis producing an average annual return of 11.34%. Currently, Gilead Sciences has a market…
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.